BridgeBio to Share Phase 3 CALIBRATE Trial Mineral Homeostasis Data in ADH1 Patients
BridgeBio will present primary results from its Phase 3 CALIBRATE trial showing encaleret restored mineral homeostasis in autosomal dominant hypocalcemia type 1 patients at the European Congress of Endocrinology May 9-12 in Prague. The company will also disclose genetic testing data for over 400 hypoparathyroidism cases and three further presentations.
1. Presentation Schedule at European Congress of Endocrinology
BridgeBio will deliver two oral presentations on May 12 in Prague: “Encaleret Restores Mineral Homeostasis in ADH1” at 11:50 am CEST and “Genetic Testing of Over 400 Individuals with Non-Surgical Hypoparathyroidism” at 12:20 pm CEST. In addition, a poster (ID P72) on baseline quality of life measures will be shown May 10-11, followed by an ePoster (ID EP260) on ADH1 epidemiology and management.
2. Phase 3 CALIBRATE Primary Results
The CALIBRATE study evaluates encaleret’s ability to normalize calcium and phosphate levels in autosomal dominant hypocalcemia type 1 patients. Primary endpoints focus on sustained mineral homeostasis, marking a critical readout for encaleret’s potential as the first targeted ADH1 therapy.
3. Genetic Testing and Disease Monitoring Data
BridgeBio’s second oral session will present genetic analysis of over 400 non-surgical hypoparathyroidism patients, identifying gain-of-function CASR variants as the most common cause. The poster sessions will provide baseline quality of life insights and a systematic literature review of ADH1 epidemiology and clinical management, supporting broader disease understanding.